Acasti Stock Analysis

ACST
 Stock
  

USD 0.60  0.01  1.64%   

The big decline in price over the last few months for Acasti Pharma could raise concerns from private investors as the firm is trading at a share price of 0.6 on 27,204 in volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Acasti Pharma or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.78. The current volatility is consistent with the ongoing market swings in August 2022 as well as with Acasti Pharma unsystematic, company-specific events.
Please continue to Trending Equities.
  
The Acasti Pharma stock analysis report makes it easy to digest most publicly released information about Acasti Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Acasti Stock analysis module also helps to analyze the Acasti Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Acasti Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The book value of Acasti Pharma was presently reported as 0.17. The company had not issued any dividends in recent years. Acasti Pharma had 1:10 split on the 15th of October 2015. Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Acasti Pharma please contact Jan DAlvise at 450 687 2262 or go to https://www.acastipharma.com.

Acasti Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Acasti Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Acasti Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Acasti Pharma generated a negative expected return over the last 90 days
Acasti Pharma has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 115 K. Net Loss for the year was (9.82 M) with profit before overhead, payroll, taxes, and interest of 120 K.
Acasti Pharma currently holds about 43.66 M in cash with (17.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 17.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acasti Pharma exotic insider transaction detected

Acasti Pharma Upcoming and Recent Events

Earnings reports are used by Acasti Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Acasti Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of February 2022
Next Financial Report28th of June 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End28th of June 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Acasti Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Acasti Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Acasti Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Acasti Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
11th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of July 2022
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
21st of June 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
18th of May 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
25th of March 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
14th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
2nd of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View

Acasti Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Acasti Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acasti Pharma backward and forwards among themselves. Acasti Pharma's institutional investor refers to the entity that pools money to purchase Acasti Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Two Sigma Securities LlcCommon Shares25.5 K22 K
Susquehanna International Group LlpCommon Shares26 K22 K
Virtu Financial LlcCommon Shares19.7 K17 K
Morgan StanleyCommon Shares18.7 K16 K
National Bank Of CanadaCommon Shares18.4 K16 K
Geode Capital Management LlcCommon Shares18.3 K15 K
Sterling Investment Advisors LtdCommon SharesKK
Note, although Acasti Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Acasti Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 27.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acasti Pharma's market, we take the total number of its shares issued and multiply it by Acasti Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (7.94) % which means that it has lost $7.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (11.98) %, meaning that it created substantial loss on money invested by shareholders. Acasti Pharma management efficiency ratios could be used to measure how well acasti pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of September, Acasti Pharma shows the mean deviation of 2.12, and Risk Adjusted Performance of (0.24). Acasti Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Acasti Pharma, which can be compared to its rivals. Please confirm Acasti Pharma coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Acasti Pharma is priced correctly, providing market reflects its regular price of 0.6 per share. As Acasti Pharma is a penny stock we also strongly suggest to validate its total risk alpha numbers.

Acasti Pharma Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Moving Average is predictive technique used to analyze Acasti Pharma price data points by creating a series of averages of different subsets of Acasti Pharma entire price series.
.

Acasti Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acasti Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acasti Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acasti Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Acasti Pharma Predictive Daily Indicators

Acasti Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Acasti Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Acasti Pharma Forecast Models

Acasti Pharma time-series forecasting models is one of many Acasti Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acasti Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Acasti Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Acasti Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acasti shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Acasti Pharma. By using and applying Acasti Stock analysis, traders can create a robust methodology for identifying Acasti entry and exit points for their positions.
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Current Acasti Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acasti analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acasti analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
6.0Strong Buy1Odds
Acasti Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Acasti analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acasti stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acasti Pharma, talking to its executives and customers, or listening to Acasti conference calls.
Acasti Analyst Advice Details

Acasti Stock Analysis Indicators

Acasti Pharma stock analysis indicators help investors evaluate how Acasti Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acasti Pharma shares will generate the highest return on investment. By understating and applying Acasti Pharma stock analysis, traders can identify Acasti Pharma position entry and exit signals to maximize returns.
Quick Ratio13.56
Fifty Two Week Low0.6100
Shares Short Prior Month871.46k
Average Daily Volume Last 10 Day52.39k
Average Daily Volume In Three Month68.91k
Shares Percent Shares Out0.74%
Short Percent Of Float0.74%
Forward Price Earnings-1.59
Float Shares33.25M
Fifty Two Week High2.3800
Enterprise Value To Ebitda0.60
Fifty Day Average0.8462
Two Hundred Day Average1.0402
Please continue to Trending Equities. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for analysis

When running Acasti Pharma price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Is Acasti Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acasti Pharma. If investors know Acasti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acasti Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Acasti Pharma is measured differently than its book value, which is the value of Acasti that is recorded on the company's balance sheet. Investors also form their own opinion of Acasti Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acasti Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acasti Pharma's market value can be influenced by many factors that don't directly affect Acasti Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Acasti Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.